Protein engineering at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
39 organizations at Antibody Engineering 2026 present work in protein engineering: 17 drug developers, 13 suppliers and service providers and 9 academic, government and non-profit bodies. Between them they bring 56 presentations to the program. Most represented: Xencor (4 on the program), Amgen (3 on the program), Genentech (3 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–12 of 39 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Chair Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Chair Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Talk Mon Dec 14 5:45pm–6:15pm Induced Proximity and Next-Generation Antibody Therapeutics Bispecifics & multispecifics |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines. | Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Chair Tue Dec 15 8:10am–8:15am Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering |
Regeneron Tarrytown, NY | |
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform. | Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Beyond oncology Chair Wed Dec 16 8:10am–8:15am |
University of Southampton Southampton, United Kingdom | |
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology. | Chair Mon Dec 14 2:25pm–2:30pm Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Chair Tue Dec 15 8:10am–8:15am |
Chugai Pharmaceutical Tokyo, Japan | |
Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies. | Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering |
City of Hope Duarte, CA | |
Cancer research and treatment center with a graduate school. | Talk Wed Dec 16 4:15pm–4:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors. |
Genmab Copenhagen, Denmark | |
Danish antibody company with marketed cancer medicines, developing bispecific antibodies and antibody-drug conjugates. | Chair Tue Dec 15 2:25pm–2:30pm Talk Wed Dec 16 11:30am–12:00pm Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces Reshaping the region where two antibody halves join, so several different antibodies can be made together in one mixture without mismatching. |
Gyes Naarden, Netherlands | |
Dutch biotech building multispecific antibodies that act only on cells co-expressing target combinations, for cancer and immune diseases. | Chair Mon Dec 14 8:00am–8:05am Chair Wed Dec 16 2:10pm–2:15pm |
Harvard University Cambridge, MA | |
Private research university, including Harvard Medical School. | Talk Mon Dec 14 2:30pm–3:00pm Discovery of G protein-coupled Receptor Modulator Antibody Fragments Small antibody fragments that switch on or block the large family of signal-receiving proteins in cell membranes. Protein engineering Talk Wed Dec 16 8:15am–8:45am A New Homotypic Interface Expands Anti-Malarial Antibody Recognition Breadth Evolving a malaria antibody so copies of it grip each other in a new way and protect against more parasite strains. Beyond oncology |
Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy. | Talk Wed Dec 16 4:45pm–5:15pm A Novel Antibody Approach to Pan-subclass IgG Reduction An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies. Beyond oncology |
Biotech with no public profile yet; on this program it co-chairs the track on engineering antibodies for difficult targets. | Talk Sun Dec 13 11:00am–11:45am Chair Mon Dec 14 2:25pm–2:30pm |
Find buyers in protein engineering
Tell us what you sell and we’ll find the people at organizations working on protein engineering most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction